Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8728944 | 0.88 | — | — | |
| SCHEMBL7499332 | 0.83 | THRB (0.42) | TSHRCA1CA2THRB | |
| SCHEMBL2919593 | 0.80 | ADRB2 (0.45) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL3519444 | 0.79 | — | — | |
| SCHEMBL4637696 | 0.78 | — | — | |
| SCHEMBL5846 | 0.75 | — | — | |
| SCHEMBL3517705 | 0.75 | — | — | |
| SCHEMBL1688880 | 0.75 | — | — | |
| SCHEMBL3630947 | 0.75 | — | — | |
| SCHEMBL20658210 | 0.75 | ADRB2 (0.41) | ADRB2ADRB1ADRB3TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997045119-A1 | USE OF SUBSTANCE P ANTAGONISTS FOR TREATING SOCIAL PHOBIA | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | claimed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| EP-2221309-B1 | NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | TOYAMA CHEMICAL CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8354426-B2 | Naphthyridine derivative monohydrate and method for producing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20100249417-A1 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2221309-A1 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | Toyama Chemical Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| WO-1995011895-A1 | N-BENZOYL-4-OXY/THIO-2-SUBSTITUTED PIPERIDINES AS SUBSTANCE-P RECEPTOR ANTAGONISTS | CIBA-GEIGY AG (CH) | 1995-05-04 | — | — | WO | disclosed |
| EP-0532456-B1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| US-5310743-A | Substance P antagonist | CIBA-GEIGY CORP. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0532456-A1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| US-4012420-A | 9,10-Secoestrane derivatives and their production | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-03-15 | — | — | US | disclosed |
| US-4001302-A | 9,10-SECOESTRANE DERIVATIVES AND THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3998847-A | 9,10-SECOESTRANE DERIVATIVES AND THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-12-21 | — | — | US | disclosed |
| US-3976701-A | Process for the preparation of 9,10-secoestrane derivatives | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-08-24 | — | — | US | disclosed |
| US-3965124-A | 6,9-Oxido-9,10-secoestrane derivatives and method of synthesis | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249417-A1 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | QDPR, NDC1, NRDC | ADRB2 4121/4885ADRB1 3262/4885ADRB3 3694/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | ADRB2 3798/4885ADRB1 3819/4885ADRB3 3999/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | ADRB2 3995/4885ADRB1 3989/4885ADRB3 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.